Results 61 to 70 of about 2,191 (125)

Use of selpercatinib in a patient with RET-mutated non-small cell lung cancer: case report

Сибирский онкологический журнал
Background. The use of the modern targeted drugs in patients with non-small-cell lung cancer (NSCLC) with certain somatic alterations (genetic alterations in EGFR, ALK, ROS1, BRAF, RET genes, etc.) provides a significant increase in overall and disease ...
A. M. Kazakov, K. K. Laktionov, V. O. Vorobyeva, K. A. Sarantseva   +3 more
doaj   +1 more source

Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review

Frontiers in Oncology
Pralsetinib and selpercatinib have been approved as specific tyrosine kinase inhibitors (TKIs) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) fusion and mutation.
Kaidiriye Setiwalidi, Yimeng Li, Yuyan Ma, Zhanpeng Hao, Yujia Zhao, Yuxin Zhang, Xuan Liang, Tao Tian, Zhiping Ruan, Yu Yao, Xiao Fu   +10 more
doaj   +1 more source

Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch

npj Precision Oncology
This case report describes the efficacy of selpercatinib, a selective RET inhibitor, in an unusual case of large-cell neuroendocrine pancreatic carcinoma (LCNEPAC) harboring a CCDC6::RET fusion.
Barbara Deschler-Baier, Markus Krebs, Matthias Kroiss, Manik Chatterjee, Daniel Gundel, Christian Kestler, Alexander Kerscher, Volker Kunzmann, Silke Appenzeller, Katja Maurus, Andreas Rosenwald, Ralf Bargou, Elena Gerhard-Hartmann, Vivek Venkataramani   +13 more
doaj   +1 more source

Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature

Frontiers in Oncology
Osimertinib, a third-generation epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI), has demonstrated significant clinical activity and tolerability in EGFR-positive non-small cell lung cancer (NSCLC) patients.
Blerina Resuli, Blerina Resuli, Heidi Galarza, Heidi Galarza, Diego Kauffmann-Guerrero, Diego Kauffmann-Guerrero, Julian Oversohl, Julian Oversohl, Jürgen Behr, Jürgen Behr, Amanda Tufman, Amanda Tufman   +11 more
doaj   +1 more source

Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET‐Altered Metastatic Thyroid Cancer or Solid Tumors

CPT: Pharmacometrics & Systems Pharmacology
Selpercatinib is a first‐in‐class, highly selective, RET kinase inhibitor with CNS activity, approved for the treatment of RET‐altered lung, thyroid, and other cancers. We report pharmacokinetic analyses to identify factors affecting selpercatinib steady‐
Dan Liu, Jan‐Stefan van derWalt
doaj   +1 more source

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer

Frontiers in Oncology
BackgroundCombined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improve the outcome of patients with advanced estrogen receptor-positive (ER+) breast cancer.
Charlotte K. Kindt, Sidse Ehmsen, Sidse Ehmsen, Sidse Ehmsen, Sofie Traynor, Benedetta Policastro, Nikoline Nissen, Mie K. Jakobsen, Monique F. Hundebøl, Lene E. Johansen, Martin Bak, Elsa Arbajian, Johan Staaf, Henrik J. Ditzel, Henrik J. Ditzel, Henrik J. Ditzel, Carla L. Alves   +16 more
doaj   +1 more source

Acquired TPM3::NTRK1 fusion as a novel off-target resistance mechanism to selpercatinib in RET-positive lung adenocarcinoma: a case report. [PDF]

Front Oncol
Choudhury R, Sharma M, Dewan A, Choudhary SK, Venkatraman P, Subbiah V, Batra U.   +6 more
europepmc   +1 more source

Redifferentiation therapy with selpercatinib in RET-fusion-positive advanced thyroid carcinoma: a case report and literature review. [PDF]

Front Oncol
Talpacci E, Morelli S, Ingriccini C, Ferrieri A, Tranfaglia C, Dottorini ME, Puxeddu E.   +6 more
europepmc   +1 more source

Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies. [PDF]

Front Endocrinol (Lausanne)
Wang J, Cao G, Liu Y, Qiao H, He Q, Zheng B.   +5 more
europepmc   +1 more source

RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases. [PDF]

Cell Rep Med
Bagheri-Yarmand R, Pagnotti GM, Kidd JL, Ramirez DA, Trupti Trivedi, Guerra L, Wang Z, Cruz LM, Moehle JM, Jebaraj YS, Wan X, Song JH, Bassett RL, Lin SH, Hu MI, Sherman SI, Hofmann MC, Guise TA.   +17 more
europepmc   +1 more source